{"673641":{"#nid":"673641","#data":{"type":"news","title":"Andrew McShan Awarded Curci Grant for Cutting-Edge Cancer Research","body":[{"value":"\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cstrong\u003E\u003Cspan\u003E\u003Cspan\u003EAndrew McShan\u003C\/span\u003E\u003C\/span\u003E\u003C\/strong\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E, assistant professor in the \u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Ca href=\u0022https:\/\/chemistry.gatech.edu\/\u0022\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003ESchool of Chemistry and Biochemistry\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E at Georgia Tech, has been awarded a prestigious Curci grant for research in cutting-edge cancer treatments.\u0026nbsp;\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EThe award, provided by the \u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Ca href=\u0022https:\/\/curcifoundation.org\/\u0022\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EShurl and Kay Curci Foundation\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E, supports innovative research at the forefront of its field. \u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EThe new funding will provide two years of support for McShan\u0027s investigation into developing the next generation of universal immunotherapies.\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u201cWe aim to understand how the immune system works and learn how it plays roles in disease,\u201d McShan says. \u201cWe\u0027re using biochemistry and structural biology to characterize biomolecules at the atomic level, and harness their intrinsic features for new therapeutic avenues.\u201d\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EMcShan\u2019s research will center on lipids \u2014 a previously understudied avenue in cancer treatment \u2014 and it has two major components: identifying new cancer lipid signatures in tumor cells, and characterizing known cancer lipid antigens to develop a \u201cmolecular blueprint\u201d for immunotherapy. Since lipid antigens provide broad, more universal signatures than current techniques, the applications of the research span a wide range of cancers and immune disorders.\u0026nbsp;\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u201cIt\u0027s a really interesting new way of thinking about this problem,\u201d McShan says. \u201cWe hope that it\u0027s a paradigm shift in the way that we think about not only general immune system functions, but also the way that you can target cancer. This same protein system also works with pathogens and autoimmune disease \u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u2014\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E it\u2019s an incredibly important system.\u201d\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\r\n\r\n\u003Ch3\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cstrong\u003E\u003Cspan\u003E\u003Cspan\u003EA new paradigm\u003C\/span\u003E\u003C\/span\u003E\u003C\/strong\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/h3\u003E\r\n\r\n\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EPreviously, immunotherapy research has largely centered on developing treatments around targeting mutated peptides, because cancer often causes these\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E mutated proteins.\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EWhile peptide-based treatments have proven to be highly effective, the strategy isn\u2019t universal \u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u2014\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E different people present different peptide mutations to the immune system. \u201cYou would have to spend years developing an immunotherapy for just one person who has one type of cancer,\u201d McShan explains, \u201cand that therapy might not work for the next person.\u201d\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EHowever, recent research indicates that lipids \u2014 fatty and waxy substances in the body that don\u0027t dissolve in water, like cholesterol \u2014 might provide a more effective avenue. \u201cLipid signals present more universal signatures to the immune system than peptides, and immune system responses to lipids are less dependent on the person,\u201d McShan says.\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EResearch into lipid-based immunotherapies has historically been limited because lipids are notoriously difficult to study in the lab. However, new tools needed to study lipids have recently become available, opening the door to this groundbreaking research.\u0026nbsp;\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EBecause these tools are so new, though, \u201ca lot of the foundational basic research hasn\u2019t been completed yet,\u201d McShan says. \u201cThis grant is a two year grant, and we plan to do this foundational research. This research will provide what the scientific community needs to start thinking about how to move lipid antigens into a clinical area.\u201d\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\r\n\r\n\u003Ch3\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cstrong\u003E\u003Cspan\u003E\u003Cspan\u003EUniversal treatments and the next generation of scientists\u003C\/span\u003E\u003C\/span\u003E\u003C\/strong\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/h3\u003E\r\n\r\n\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EWhile McShan\u2019s research team will focus on cancer for the Curci grant, lipid-based treatments could open the door for additional cost-effective, timely treatments \u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u2014\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E treatments that could also apply to multiple types of cancers, and to other diseases. \u201cIf we can understand these cancer lipid antigens \u2014 how they\u0027re functioning and what they\u2019re doing \u2014 there is a translation to the other applications in immunotherapy,\u201d McShan says.\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u201cThe protein that we\u0027re studying, called CD1, plays roles in nearly every immunological response or disease,\u201d McShan adds. \u201cThis type of research could be important for responses to viral infection, bacteria and parasite pathogens, and autoimmune disease.\u201d\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003ELipids can aid in the development of new and improved vaccines. For example, a lipid-based tuberculosis vaccine has been shown to have the same efficacy as a tuberculosis vaccine made from a live attenuated bacterium. \u201cIf we were to discover new cancer lipids \u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u2014\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E these could potentially be used as prophylactic cancer vaccines,\u201d McShan says.\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003EAs a newer member of the Georgia Tech community, McShan is also already making an impact across the campus community. \u201cWe care a lot about making science accessible, and being equitable and inclusive,\u201d McShan, who joined the \u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Ca href=\u0022https:\/\/chemistry.gatech.edu\/new-faculty-members\u0022\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003ECollege of Sciences faculty in summer 2022\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E, says. \u201cOur lab is almost entirely women, and so the research that this grant is going to support is also going to support the next generation of women doing science amazing science \u2014 and that\u2019s something that gets me really excited.\u201d\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n","summary":"","format":"limited_html"}],"field_subtitle":"","field_summary":[{"value":"\u003Cp\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cem\u003E\u003Cspan\u003EThe two-year grant will support McShan\u2019s innovative research on lipid-based immunotherapies, which could \u003C\/span\u003E\u003C\/em\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cspan\u003E\u003Cem\u003E\u003Cspan\u003Ehelp develop the next generation of universal immunotherapies.\u003C\/span\u003E\u003C\/em\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/span\u003E\u003C\/p\u003E\r\n","format":"limited_html"}],"field_summary_sentence":[{"value":"The grant will support innovative research on lipid-based immunotherapies, which could help develop the next generation of universal immunotherapies."}],"uid":"35599","created_gmt":"2024-03-21 14:50:42","changed_gmt":"2024-03-26 00:32:36","author":"sperrin6","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2024-03-25T00:00:00-04:00","iso_date":"2024-03-25T00:00:00-04:00","tz":"America\/New_York"},"extras":[],"hg_media":{"673456":{"id":"673456","type":"image","title":"Andrew McShan","body":null,"created":"1711032511","gmt_created":"2024-03-21 14:48:31","changed":"1711032492","gmt_changed":"2024-03-21 14:48:12","alt":"Andrew McShan","file":{"fid":"256854","name":"McShan_photo.jpeg","image_path":"\/sites\/default\/files\/2024\/03\/21\/McShan_photo.jpeg","image_full_path":"http:\/\/hg.gatech.edu\/\/sites\/default\/files\/2024\/03\/21\/McShan_photo.jpeg","mime":"image\/jpeg","size":96566,"path_740":"http:\/\/hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/2024\/03\/21\/McShan_photo.jpeg?itok=aCepzxdB"}}},"media_ids":["673456"],"groups":[{"id":"1278","name":"College of Sciences"},{"id":"85951","name":"School of Chemistry and Biochemistry"}],"categories":[{"id":"138","name":"Biotechnology, Health, Bioengineering, Genetics"},{"id":"140","name":"Cancer Research"},{"id":"141","name":"Chemistry and Chemical Engineering"},{"id":"146","name":"Life Sciences and Biology"},{"id":"135","name":"Research"}],"keywords":[{"id":"192249","name":"cos-community"},{"id":"193266","name":"cos-research"},{"id":"192250","name":"cos-microbial"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[{"id":"71871","name":"Campus and Community"}],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003EWritten by Selena Langner\u003C\/p\u003E\r\n\r\n\u003Cp\u003EContact: \u003Ca href=\u0022mailto: jess.hunt@cos.gatech.edu\u0022\u003EJess Hunt-Ralston\u003C\/a\u003E\u003C\/p\u003E\r\n","format":"limited_html"}],"email":["jess@cos.gatech.edu"],"slides":[],"orientation":[],"userdata":""}}}